Corporate Name Officially Changed to Pacific Biomarkers, Inc. from Pacific Biometrics, Inc.
Pacific Biomarkers, Inc. (OTC Bulletin Board: PBME), which provides specialty reference biomarker services to support pharmaceutical and laboratory diagnostic manufacturers in the conduct of human clinical research, announced that its corporate name has been officially changed to Pacific Biomarkers, Inc. The name was approved by shareholders and the State of Washington in December 2009. At the present time, the Company is waiting for a pending change in its stock symbol. In the meantime, the shares continue to trade on the OTC Bulletin Board under the symbol "PBME".
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
